Elevance Health - ELV Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $587.42
Forecasted Upside: 7.25%
Number of Analysts: 13
Breakdown:
0 Sell Ratings
1 Hold Ratings
12 Buy Ratings
0 Strong Buy Ratings

^$547.71 As of 05/17/2024 01:00 AM ET

▲ +3.82 (0.70%)

1 month | 3 months | 12 months

Get New Elevance Health Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ELV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELV

^$587.42

▲ +7.25% Upside Potential

This price target is based on 13 analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is $587.42, with a high forecast of $621.00 and a low forecast of $552.00. The average price target represents a 7.25% upside from the last price of $547.71.

Current Consensus is Moderate Buy

The current consensus among 13 polled investment analysts is to moderate buy stock in Elevance Health. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
12 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

11/24/2022

0 strong buy ratings
12 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

2/22/2023

0 strong buy ratings
12 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

5/23/2023

0 strong buy ratings
12 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

8/21/2023

0 strong buy ratings
12 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

11/19/2023

0 strong buy ratings
12 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

2/17/2024

0 strong buy ratings
12 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

4/17/2024

0 strong buy ratings
12 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

5/17/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/24/2024	Mizuho	Boost Target	Buy ➝ Buy	$575.00 ➝ $585.00	Low
4/19/2024	Royal Bank of Canada	Boost Target	Outperform ➝ Outperform	$574.00 ➝ $575.00	Low
4/19/2024	UBS Group	Boost Target	Buy ➝ Buy	$585.00 ➝ $605.00	Low
4/19/2024	Truist Financial	Reiterated Rating	Buy ➝ Buy	$580.00 ➝ $600.00	Low
4/19/2024	Wells Fargo & Company	Boost Target	Overweight ➝ Overweight	$557.00 ➝ $600.00	Low
4/19/2024	Barclays	Boost Target	Overweight ➝ Overweight	$584.00 ➝ $621.00	Low
4/19/2024	Jefferies Financial Group	Boost Target	Buy ➝ Buy	$602.00 ➝ $604.00	Low
4/10/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$580.00	Low
4/8/2024	Wells Fargo & Company	Lower Target	Overweight ➝ Overweight	$561.00 ➝ $557.00	Low
4/4/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$580.00	Low
3/6/2024	Barclays	Initiated Coverage	Overweight	$584.00	Low
2/14/2024	Cantor Fitzgerald	Boost Target	Overweight ➝ Overweight	$547.00 ➝ $580.00	Low
2/2/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$547.00	Low
1/25/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$547.00	Low
1/25/2024	Royal Bank of Canada	Boost Target	Outperform ➝ Outperform	$572.00 ➝ $574.00	Low
1/19/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$547.00	Low
11/21/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$547.00	Low
11/17/2023	JPMorgan Chase & Co.	Lower Target	Overweight ➝ Overweight	$569.00 ➝ $552.00	Low
10/19/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$547.00	Low
10/19/2023	Morgan Stanley	Boost Target	Overweight ➝ Overweight	$585.00 ➝ $587.00	Low
9/14/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$547.00	Low
7/25/2023	Morgan Stanley	Boost Target	Overweight	$571.00 ➝ $585.00	Low
7/24/2023	TD Cowen	Boost Target	Outperform	$564.00 ➝ $585.00	Low
7/20/2023	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$572.00	Low
7/20/2023	Stephens	Reiterated Rating	Overweight ➝ Overweight	$555.00	Low
7/12/2023	Wolfe Research	Downgrade	Outperform ➝ Peer Perform		Low
7/7/2023	JPMorgan Chase & Co.	Lower Target		$572.00 ➝ $535.00	Low
6/20/2023	Truist Financial	Lower Target		$580.00 ➝ $560.00	Low
4/27/2023	22nd Century Group	Reiterated Rating	Upgrade		Low
4/27/2023	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$500.00 ➝ $571.00	Low
4/24/2023	Wells Fargo & Company	Lower Target		$597.00 ➝ $561.00	Low
4/21/2023	Loop Capital	Lower Target	Buy	$565.00 ➝ $550.00	Low
4/20/2023	Cantor Fitzgerald	Initiated Coverage	Overweight	$547.00	Low
4/20/2023	Deutsche Bank Aktiengesellschaft	Boost Target		$571.00 ➝ $575.00	Low
4/20/2023	TD Cowen	Lower Target	Outperform	$577.00 ➝ $564.00	Low
3/28/2023	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$523.00 ➝ $572.00	Low
3/24/2023	Truist Financial	Lower Target	Buy	$610.00 ➝ $580.00	Low
3/21/2023	Wells Fargo & Company	Lower Target	Equal Weight	$609.00 ➝ $597.00	Low
3/8/2023	Deutsche Bank Aktiengesellschaft	Lower Target	Buy	$581.00 ➝ $571.00	Low
2/23/2023	JPMorgan Chase & Co.	Boost Target	Overweight	$555.00 ➝ $572.00	Low
1/30/2023	Loop Capital	Boost Target		$550.00 ➝ $565.00	Low
1/26/2023	Royal Bank of Canada	Boost Target	Sector Perform	$505.00 ➝ $523.00	Low
1/26/2023	SVB Leerink	Reiterated Rating	Outperform	$580.00	Low
1/4/2023	Wells Fargo & Company	Boost Target	Overweight	$557.00 ➝ $609.00	Low
11/10/2022	Mizuho	Boost Target	Buy	$545.00 ➝ $575.00	Low
10/24/2022	UBS Group	Boost Target		$585.00 ➝ $610.00	Low
10/21/2022	Morgan Stanley	Boost Target	Equal Weight	$485.00 ➝ $500.00	Low
10/21/2022	Deutsche Bank Aktiengesellschaft	Boost Target	Buy	$576.00 ➝ $581.00	Low
9/9/2022	Bank of America	Upgrade	Neutral ➝ Buy	$535.00 ➝ $575.00	Low
8/22/2022	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$490.00 ➝ $580.00	Low
7/25/2022	Morgan Stanley	Lower Target	Equal Weight	$533.00 ➝ $485.00	Low
7/22/2022	Stephens	Lower Target		$550.00	Low
7/22/2022	Cowen	Lower Target		$577.00	Low
7/22/2022	SVB Leerink	Lower Target	Market Perform ➝ Market Perform	$555.00 ➝ $490.00	Low
7/21/2022	Royal Bank of Canada	Lower Target		$544.00 ➝ $505.00	Low
6/22/2022	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$607.00 ➝ $533.00	Low
6/16/2022	Loop Capital	Initiated Coverage	Buy	$550.00	High
5/26/2022	Sanford C. Bernstein	Initiated Coverage	Outperform	$577.00 ➝ $596.00	Medium
5/25/2022	Wells Fargo & Company	Lower Target	Overweight	$586.00 ➝ $580.00	Low
5/4/2022	Mizuho	Boost Target		$510.00 ➝ $545.00	High
4/25/2022	BMO Capital Markets	Boost Target	Outperform	$540.00 ➝ $625.00	Medium
4/22/2022	Wells Fargo & Company	Set Target	Overweight	$460.00 ➝ $586.00	High
4/22/2022	Deutsche Bank Aktiengesellschaft	Boost Target	Buy	$453.00 ➝ $574.00	High
4/21/2022	Cowen	Boost Target		$472.00 ➝ $642.00	Medium
4/21/2022	Jefferies Financial Group	Boost Target		$575.00 ➝ $625.00	Low
4/21/2022	Truist Financial	Boost Target		$590.00 ➝ $610.00	High
4/21/2022	Cowen	Boost Target		$472.00 ➝ $642.00	High
4/21/2022	Morgan Stanley	Boost Target	Overweight	$518.00 ➝ $607.00	High
4/21/2022	SVB Leerink	Boost Target	Market Perform	$483.00 ➝ $555.00	Medium
4/21/2022	The Goldman Sachs Group	Boost Target	Buy	$527.00 ➝ $605.00	Medium
4/21/2022	Credit Suisse Group	Boost Target	Outperform	$518.00 ➝ $584.00	High
4/7/2022	Truist Financial	Boost Target		$540.00 ➝ $590.00	Medium
3/29/2022	Jefferies Financial Group	Reiterated Rating	Buy ➝ Buy	$559.00	Low
3/29/2022	UBS Group	Boost Target	Buy	$477.00 ➝ $541.00	High
3/15/2022	SVB Leerink	Boost Target	Market Perform	$465.00 ➝ $483.00	Medium
2/7/2022	Argus	Boost Target	Buy	$475.00 ➝ $500.00	Medium
1/28/2022	Morgan Stanley	Lower Target	Overweight	$561.00 ➝ $518.00	Low
1/27/2022	SVB Leerink	Boost Target	Market Perform	$430.00 ➝ $465.00	Medium
1/11/2022	Sanford C. Bernstein	Boost Target		$559.00 ➝ $574.00	Medium
1/5/2022	Truist Financial	Boost Target	Buy ➝ Buy	$490.00 ➝ $540.00	Medium
12/20/2021	Mizuho	Upgrade	Neutral ➝ Buy	$450.00 ➝ $510.00	Medium
12/17/2021	Morgan Stanley	Boost Target	Overweight	$486.00 ➝ $561.00	Medium
12/14/2021	The Goldman Sachs Group	Initiated Coverage	Conviction-Buy	$517.00	Low
10/29/2021	Mizuho	Boost Target	Neutral	$385.00 ➝ $450.00	Low
10/25/2021	Argus	Boost Target	Buy	$435.00 ➝ $475.00	Low
10/25/2021	Wells Fargo & Company	Boost Target	Overweight	$460.00 ➝ $500.00	Low
10/22/2021	BMO Capital Markets	Boost Target	Outperform	$465.00 ➝ $500.00	Low
10/22/2021	Deutsche Bank Aktiengesellschaft	Boost Target	Buy	$408.00 ➝ $460.00	Low
10/21/2021	Truist Financial	Boost Target	Buy	$450.00 ➝ $490.00	High
10/21/2021	Morgan Stanley	Boost Target	Overweight	$468.00 ➝ $486.00	High
10/21/2021	SVB Leerink	Boost Target	Market Perform	$403.00 ➝ $430.00	High
10/21/2021	Credit Suisse Group	Boost Target	Outperform	$425.00 ➝ $486.00	High
10/21/2021	Royal Bank of Canada	Boost Target	Sector Perform	$408.00 ➝ $452.00	High
10/21/2021	Stephens	Boost Target	Overweight	$440.00 ➝ $475.00	High
10/21/2021	Barclays	Boost Target	Overweight	$450.00 ➝ $485.00	High
10/21/2021	Citigroup	Boost Target	Buy	$445.00 ➝ $497.00	High
9/27/2021	SVB Leerink	Initiated Coverage	Market Perform	$403.00	High
9/9/2021	Cowen	Initiated Coverage	Outperform	$465.00	High
8/31/2021	Morgan Stanley	Boost Target	Overweight	$459.00 ➝ $468.00	High
7/22/2021	Jefferies Financial Group	Boost Target	Buy	$447.00 ➝ $453.00	Low
7/22/2021	Stephens	Boost Target	Overweight	$430.00 ➝ $440.00	Low
7/22/2021	BMO Capital Markets	Boost Target	Outperform	$450.00 ➝ $465.00	Low
7/22/2021	Barclays	Boost Target	Overweight	$425.00 ➝ $450.00	Low
7/22/2021	Cantor Fitzgerald	Boost Target	Overweight	$430.00 ➝ $455.00	Low
7/22/2021	Mizuho	Boost Target	Neutral	$380.00 ➝ $385.00	Low
7/22/2021	Royal Bank of Canada	Boost Target	Sector Perform	$399.00 ➝ $408.00	Low
7/9/2021	Seaport Res Ptn	Reiterated Rating	Buy		Low
7/2/2021	Morgan Stanley	Boost Target	Overweight	$454.00 ➝ $459.00	Medium
6/10/2021	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$399.00	Low
5/24/2021	Wells Fargo & Company	Initiated Coverage	Overweight	$460.00	N/A
5/18/2021	Wells Fargo & Company	Initiated Coverage	Overweight	$460.00	Low
5/6/2021	Argus	Boost Target	Average ➝ Buy	$330.00 ➝ $435.00	Low
5/3/2021	Mizuho	Boost Target	Neutral	$320.00 ➝ $380.00	Medium
4/22/2021	Truist Financial	Boost Target		$425.00 ➝ $450.00	Low
4/22/2021	Stephens	Boost Target	Overweight	$395.00 ➝ $430.00	Low
4/22/2021	BMO Capital Markets	Boost Target	Outperform	$440.00 ➝ $450.00	Low
4/22/2021	Royal Bank of Canada	Boost Target	Outperform	$350.00 ➝ $399.00	Low
4/22/2021	Barclays	Boost Target	Overweight	$375.00 ➝ $425.00	Low
4/20/2021	Truist Financial	Boost Target	Buy	$425.00 ➝ $450.00	Low
4/14/2021	Truist Financial	Boost Target		$375.00 ➝ $425.00	High
4/14/2021	Cowen	Boost Target	Outperform	$360.00 ➝ $395.00	Low
3/9/2021	Truist Financial	Upgrade	Hold ➝ Buy	$360.00 ➝ $375.00	Low
3/4/2021	Truist Financial	Upgrade	Hold ➝ Buy	$360.00 ➝ $375.00	High
1/28/2021	Credit Suisse Group	Lower Target	Outperform	$389.00 ➝ $382.00	High
1/28/2021	Stephens	Lower Target	Overweight	$350.00 ➝ $340.00	High
1/26/2021	Cowen	Boost Target	Outperform	$330.00 ➝ $360.00	Medium
1/15/2021	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$305.00 ➝ $402.00	Medium
1/13/2021	Argus	Boost Target	Outperform ➝ Buy	$300.00 ➝ $380.00	Low
1/5/2021	Truist Financial	Boost Target		$320.00 ➝ $360.00	N/A
12/18/2020	Mizuho	Boost Target	Neutral	$300.00 ➝ $320.00	High
12/14/2020	SVB Leerink	Boost Target	Outperform	$370.00 ➝ $400.00	Low
11/11/2020	Piper Sandler	Boost Target	Overweight	$330.00 ➝ $369.00	High
11/6/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$324.00 ➝ $389.00	Low
10/29/2020	Deutsche Bank Aktiengesellschaft	Lower Target	Buy	$349.00 ➝ $337.00	Medium
10/29/2020	Smith Barney Citigroup	Boost Target		$325.00 ➝ $338.00	Medium
10/29/2020	SVB Leerink	Boost Target	Outperform	$345.00 ➝ $370.00	High
7/30/2020	Deutsche Bank Aktiengesellschaft	Lower Target	Buy	$362.00 ➝ $349.00	Low
7/30/2020	Royal Bank of Canada	Boost Target	Outperform	$319.00 ➝ $331.00	Medium
7/30/2020	SVB Leerink	Boost Target	Outperform	$325.00 ➝ $345.00	Low
7/10/2020	Jefferies Financial Group	Boost Target	Hold	$271.00 ➝ $281.00	Low
7/1/2020	SVB Leerink	Initiated Coverage	Outperform	$325.00	Medium
6/9/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$360.00	Medium
6/5/2020	The Goldman Sachs Group	Initiated Coverage	Neutral	$340.00	High
5/21/2020	SunTrust Banks	Boost Target	Hold	$280.00 ➝ $320.00	Low
5/12/2020	UBS Group	Boost Target	Buy	$307.00 ➝ $330.00	Low
4/30/2020	Morgan Stanley	Boost Target	Overweight	$310.00 ➝ $423.00	High
4/29/2020	Cfra	Upgrade	Hold ➝ Buy	$290.00 ➝ $306.00	Medium
4/13/2020	Morgan Stanley	Boost Target	Overweight	$291.00 ➝ $310.00	Low
4/13/2020	SunTrust Banks	Lower Target	Hold	$330.00 ➝ $280.00	Low
4/12/2020	Royal Bank of Canada	Reiterated Rating	Buy	$319.00	Low
4/9/2020	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$257.00	Medium
3/27/2020	Morgan Stanley	Lower Target	Buy	$374.00 ➝ $291.00	Low
2/18/2020	Deutsche Bank Aktiengesellschaft	Boost Target	Buy	$314.00 ➝ $362.00	Medium
1/31/2020	Morgan Stanley	Lower Target	Overweight	$382.00 ➝ $374.00	Low
1/31/2020	Credit Suisse Group	Lower Target	Outperform	$380.00 ➝ $355.00	Low
1/31/2020	Deutsche Bank Aktiengesellschaft	Lower Target	Buy	$319.00 ➝ $314.00	Low
1/30/2020	Bank of America	Lower Target	Neutral	$330.00 ➝ $324.00	Medium
1/29/2020	Stephens	Lower Target	Overweight	$345.00 ➝ $330.00	High
1/8/2020	Credit Suisse Group	Boost Target	Outperform	$340.00 ➝ $380.00	Medium
1/3/2020	Evercore ISI	Upgrade	In-Line ➝ Outperform		Medium
12/20/2019	JPMorgan Chase & Co.	Boost Target	Overweight	$322.00 ➝ $391.00	Medium
12/6/2019	Bank of America	Downgrade	Buy ➝ Neutral		Low
10/24/2019	Credit Suisse Group	Lower Target	Outperform	$345.00 ➝ $340.00	Low
10/17/2019	Mizuho	Initiated Coverage	Neutral	$262.00	Low
9/26/2019	Morgan Stanley	Lower Target	Overweight	$371.00 ➝ $356.00	Low
9/12/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy		Low
7/26/2019	Wells Fargo & Company	Reiterated Rating	Buy		N/A
7/12/2019	Morgan Stanley	Boost Target	Overweight	$359.00 ➝ $371.00	Low

(Data available from 5/18/2019 forward)

News Sentiment Rating

1.00 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

37 very positive mentions
22 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

10/21/2023

10 very positive mentions
14 positive mentions
5 negative mentions
0 very negative mentions

Mentions as of

11/20/2023

34 very positive mentions
16 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

12/20/2023

29 very positive mentions
7 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

1/19/2024

40 very positive mentions
35 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

2/18/2024

32 very positive mentions
16 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/19/2024

30 very positive mentions
31 positive mentions
6 negative mentions
0 very negative mentions

Mentions as of

4/18/2024

42 very positive mentions
25 positive mentions
5 negative mentions
0 very negative mentions

Mentions as of

5/18/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $547.71

$541.41

$547.99

50 Day Range

MA: $520.57

$497.60

$547.71

52 Week Range

Now: $547.71

$412.00

$547.99

Volume

897,567 shs

Average Volume

924,119 shs

Market Capitalization

$127.30 billion

P/E Ratio

20.70

Dividend Yield

1.20%

Beta

0.79

Frequently Asked Questions

What sell-side analysts currently cover shares of Elevance Health?: The following Wall Street sell-side analysts have issued reports on Elevance Health in the last year: Barclays PLC, Cantor Fitzgerald, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Morgan Stanley, Royal Bank of Canada, Stephens, StockNews.com, TD Cowen, Truist Financial Co., UBS Group AG, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for ELV.
What is the current price target for Elevance Health?: 12 Wall Street analysts have set twelve-month price targets for Elevance Health in the last year. Their average twelve-month price target is $587.42, suggesting a possible upside of 7.2%. Barclays PLC has the highest price target set, predicting ELV will reach $621.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $552.00 for Elevance Health in the next year.
View the latest price targets for ELV.
What is the current consensus analyst rating for Elevance Health?: Elevance Health currently has 1 hold rating and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ELV.
What other companies compete with Elevance Health?: Other companies that are similar to Elevance Health include The Cigna Group, Humana, Centene, UnitedHealth Group and Stryker. Learn More about companies similar to Elevance Health.
How do I contact Elevance Health's investor relations team?: Elevance Health's physical mailing address is 220 VIRGINIA AVENUE, INDIANAPOLIS IN, 46204. The company's listed phone number is (800) 331-1476 and its investor relations email address is [email protected]. The official website for Elevance Health is www.antheminc.com. Learn More about contacing Elevance Health investor relations.

Elevance Health - ELV Stock Price Target and Predictions

Analyst Price Target for ELV

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

1.00 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Elevance Health?

What is the current price target for Elevance Health?

What is the current consensus analyst rating for Elevance Health?

What other companies compete with Elevance Health?

How do I contact Elevance Health's investor relations team?